A role for EMT in CD73 regulation in breast cancer. (31st December 2022)

• Record Type: Journal Article
• Authors: Hasmim, Meriem; Berchem, Guy; Janji, Bassam
• Is Part Of: Oncoimmunology. Volume 11:Number 1(2022)
• Publication Date: 2022-12-31
• Subjects: CD73 -- SNAI1 -- epithelial-to-mesenchymal transition -- adenosine -- triple negative breast cancer -- immunotherapy; Tumors -- Immunological aspects -- Periodicals; Neoplasms -- therapy -- Periodicals; Immunotherapy -- Periodicals; 616.994
• DOI: 10.1080/2162402X.2022.2152636
• Languages: English
• ISSNs: 2162-402X

Abstract

ABSTRACT: CD73 is an emerging target in cancer due to its role in generating adenosine, a potent immunosuppressor. We found that SNAI1, a driver of epithelial-to-mesenchymal transition (EMT), upregulates CD73 in triple negative breast cancer cells. Here, we discuss the relevance of improving CD73-based therapy by combining with inhibitors of EMT.